Discounted Cash Flow Rating

Buy

Return on Equity Rating

Neutral

Debt to Equity Rating

Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Sanofi American Depositary Shares (Each representing one-half of one ordinary share) (SNY)

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

07/01/2002

Market Cap

136,080,891,744

Shares Outstanding

1,264,800,000

Weighted SO

2,502,699,162

Total Employees

N/A

Upcoming Earnings

07/25/2024

Similar Tickers

AZN --.--%

RHHBY --.--%

GSK --.--%

MRK --.--%

NVS --.--%

BMY --.--%

GILD --.--%

BAYRY --.--%

AMGN --.--%

Beta

0.4150

Last Div

2.0400

Range

42.63-55.72

Chg

0.2699

Avg Vol

2299709

Mkt Cap

136080891744

Exch

NASDAQ

Country

FR

Phone

33 1 53 77 40 00

DCF Diff

-39.9420

DCF

93.9620

Div Yield

0.0272

P/S

1.8202

EV Multiple

6.9504

P/FV

1.6944

Div Yield %

2.7225

P/E

15.6423

PEG

4.2022

Payout

0.5974

Current Ratio

1.0017

Quick Ratio

0.6484

Cash Ratio

0.2263

DSO

47.3262

DIO

166.9664

Op Cycle

214.2926

DPO

116.9819

CCC

97.3106

Gross Margin

0.6585

Op Margin

0.2194

Pretax Margin

0.1478

Net Margin

0.1160

Eff Tax Rate

0.2054

ROA

0.0607

ROE

0.1071

ROCE

0.1494

NI/EBT

0.7845

EBT/EBIT

0.6737

EBIT/Rev

0.2194

Debt Ratio

0.1697

D/E

0.3029

LT Debt/Cap

0.1468

Total Debt/Cap

0.2325

Int Coverage

10.1347

CF/Debt

0.3687

Equity Multi

1.7850

Rec Turnover

7.7124

Pay Turnover

3.1201

Inv Turnover

2.1861

FA Turnover

5.7162

Asset Turnover

0.5234

OCF/Share

3.2503

FCF/Share

1.6348

Cash/Share

2.7206

OCF/Sales

0.1195

FCF/OCF

0.5030

CF Coverage

0.3687

ST Coverage

0.8532

CapEx Coverage

2.0119

Div&CapEx Cov

0.9289

P/BV

1.6944

P/B

1.6944

P/S

1.8202

P/E

15.6423

P/FCF

30.2741

P/OCF

15.1721

P/CF

15.1721

PEG

4.2022

P/S

1.8202

EV Multiple

6.9504

P/FV

1.6944

DPS

1.4780

Latest Headlines (EST)

GlobeNewswire Inc. Jun 25, 05:00 Communiqué de presse : Le riliprubart est désigné comme médicament orphelin aux États-Unis pour le rejet induit par les anticorps dans la transplantation d’organes solides GlobeNewswire Inc. Jun 25, 05:00 Press Release: Riliprubart earns orphan drug designation in the US for antibody-mediated rejection in solid organ transplantation GlobeNewswire Inc. Jun 07, 22:30 Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color GlobeNewswire Inc. May 30, 05:00 Communiqué de presse : L’itépekimab a satisfait au critère d’évaluation principal dans l’une des deux études de phase 3 sur la BPCO GlobeNewswire Inc. May 30, 05:00 Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials GlobeNewswire Inc. May 30, 05:00 Press Release: Itepekimab met the primary endpoint in one of two COPD phase 3 studies GlobeNewswire Inc. May 22, 04:59 Temenos sets new benchmark for scalability of AI-powered banking with Microsoft GlobeNewswire Inc. May 22, 04:55 Temenos survey reveals banks doubling down on technology modernization to drive customer experience Benzinga May 21, 23:30 Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi GlobeNewswire Inc. May 21, 23:30 Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi GlobeNewswire Inc. May 21, 23:15 Communiqué de presse : Sanofi va acquérir Vigil Neuroscience, Inc. et ajouter un nouveau médicament expérimental pour le traitement de la maladie d’Alzheimer à son portefeuille en neurologie GlobeNewswire Inc. May 21, 23:15 Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline GlobeNewswire Inc. Apr 03, 22:13 Anne Whitaker Appointed as Non-Executive Director GlobeNewswire Inc. Apr 03, 05:00 Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines GlobeNewswire Inc. Mar 20, 05:22 Temenos abrirá un centro de innovación de tecnología bancaria en Florida Central GlobeNewswire Inc. Mar 20, 05:22 Temenos ouvre un centre d’innovation en matière de technologies bancaires en Floride centrale GlobeNewswire Inc. Mar 20, 05:22 Temenos eröffnet Innovationszentrum für Bankentechnologie in Zentralflorida The Motley Fool Mar 08, 15:02 Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? GlobeNewswire Inc. Feb 20, 02:30 Refractories Market worth $42.4 billion by 2029, at a CAGR of 4.4%, says MarketsandMarkets™ GlobeNewswire Inc. Feb 18, 05:59 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)

Revenue Product Segmentation

Dividend History

Cash Value Ex-Dividend Date Declaration Date Record Date Pay Date
2.20 05/09/2024 03/26/2024 05/10/2024 06/06/2024
2.04 05/30/2023 05/30/2023 05/31/2023 06/23/2023
1.38 05/25/2023 02/15/2023 11/30/-0001 06/23/2023
0.32 05/26/2022 11/30/-0001 05/27/2022 06/27/2022
1.84 05/04/2022 04/20/2022 05/05/2022 05/31/2022
1.93 05/03/2021 03/23/2021 05/04/2021 05/26/2021
1.75 04/30/2020 03/05/2020 05/01/2020 05/26/2020
1.74 05/07/2019 02/26/2019 05/08/2019 05/31/2019
1.86 05/09/2018 02/13/2018 05/10/2018 06/04/2018
1.58 05/11/2017 02/17/2017 05/15/2017 06/07/2017
1.63 05/05/2016 02/22/2016 05/09/2016 06/01/2016
1.62 05/06/2015 02/26/2015 05/08/2015 06/02/2015
2.64 05/07/2014 11/30/-0001 11/30/-0001 06/05/2014
12.15 05/06/2013 11/30/-0001 11/30/-0001 06/05/2013
11.35 05/07/2012 11/30/-0001 11/30/-0001 05/30/2012
12.96 05/11/2011 11/30/-0001 11/30/-0001 06/24/2011
101.16 05/17/2010 11/30/-0001 11/30/-0001 11/30/-0001
92.98 04/20/2009 11/30/-0001 11/30/-0001 11/30/-0001
117.15 05/16/2008 11/30/-0001 11/30/-0001 11/30/-0001
76.85 06/04/2007 11/30/-0001 11/30/-0001 11/30/-0001
58.69 06/02/2006 11/30/-0001 11/30/-0001 11/30/-0001
48.91 06/02/2005 11/30/-0001 11/30/-0001 11/30/-0001
1.86 09/27/2004 11/30/-0001 11/30/-0001 11/30/-0001
34.62 04/30/2004 11/30/-0001 11/30/-0001 11/30/-0001
27.26 05/28/2003 11/30/-0001 11/30/-0001 11/30/-0001